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Abstract
Aims/hypothesis Although increasing hyperglycaemia, arteri-
al hypertension and longer duration of diabetes raise the risk
of progression of diabetic retinopathy, short-term benefits in
terms of improved metabolic control and lowered blood pres-
sure have not been demonstrated. We therefore examined the
effect of changes in glycaemia and arterial blood pressure on
the incidence of clinically significant macular oedema in a
population of diabetic patients.
Methods We performed a retrospective review of all patients
with type 1 diabetes who attended the retinopathy screening
clinic at the Steno Diabetes Center from 1988 to 2008, using
the endpoint referral to first photocoagulation treatment for
clinically significant diabetic macular oedema. The analysis
included 1,878 patients (median observation, 8 years).
Changes were defined as the inter-visit change; in the case
of an event the last event-free interval before referral, where
the median screening interval was 6 months.
Results Risk of progression to photocoagulation for macular
oedema increased with duration of diabetes (p <0.001), cur-
rent HbA1c (p <0.0001) and with the magnitude of changes in
HbA1c (p =0.0002) and systolic blood pressure (p <0.0001) in
a multiple regression model. A recent decrease of ≥0.5 per-
centage points or an increase in HbA1c of >0.5 percentage
points per 6 months was associated with HRs of 3.04 and
1.28, respectively, compared with lesser changes in HbA1c.
Conclusions/interpretation In this study, large recent changes
in metabolic control and systolic blood pressure, irrespective
of direction, were independent risk factors for progression to
photocoagulation for diabetic macular oedema. The effects of
metabolic and haemodynamic stability on diabetic retinopathy
should be examined in prospective studies.
Keywords Blood pressure . Clinically significant macular
oedema . HbA1c . Risk factors . Type 1 diabetes
Abbreviations
CSME Clinically significant macular oedema
ETDRS Early Treatment Diabetic Retinopathy Study
Introduction
Diabetic macular oedema is a sight-threatening complication
of diabetic retinopathy [1–4]. Risk factors identified in previ-
ous studies include duration of diabetes, hyperglycaemia, and
arterial hypertension [2, 5–11]. The 25 year follow-up of the
Wisconsin Epidemiological Study of Diabetic Retinopathy
showed that both baseline glycaemia and an increase in
glycaemia from baseline to year four were significant risk
factors for progression to diabetic macular oedema [12].
In the DCCT the short-term response to intensified insulin
treatment in type 1 diabetes was an accelerated progression of
diabetic retinopathy. It was only after approximately one year
that the rate of progression among patients on intensified
insulin therapy fell below that of the conventional therapy
group, where it remained for the duration of the 9 year study
[13–15]. The observed progression events were largely sub-
clinical. In addition, a later report has shown that the variability
of metabolic regulation is associated with microvascular com-
plications [16, 17]. In the present study, we examined the effect
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of changes in metabolic control and blood pressure in a routine
clinical setting on an outcome of clinical impact, namely
photocoagulation for clinically significant macular oedema,
in 1,878 patients with type 1 diabetes attending the diabetic
retinopathy screening clinic of the Steno Diabetes Center.
Methods
Patients The study population consisted of all patients with
type 1 diabetes who attended the diabetic retinopathy screen-
ing clinic at the Steno Diabetes Center between the initiation
of systematic retinopathy screening in 1988 and the end of
2008, of which 50% started screening before September 1993.
The Steno Diabetes Center provides primary diabetes care for
a large, geographically defined subset of patients with type 1
diabetes who reside in the greater Copenhagen area. Having
type 1 diabetes was defined as undergoing insulin therapy and
having received a diagnosis of diabetes before 30 years of age.
Before 1996, the study population included children, whereas
after 1996 only patients aged 16 years and older attended the
clinic. Because diabetic retinopathy in general and diabetic
macular oedema in particular are very rare in patients younger
than 19 years this change in the composition of the study
population is unlikely to impact study outcomes [10].
Screening procedure Retinopathy screening comprised, as a
minimum, automated refractioning, determination of best-
corrected visual acuity, andmydriatic non-stereoscopic fundus
photography. Stereoscopic fundus photography was used,
however, up until the introduction of digital fundus photogra-
phy in 2003. Retinopathy was graded and classified using the
five-step Steno retinopathy scale, which assigns diabetic mac-
ular oedema to level 3 out of 5 [18]. The interval to the next
screening examination was set as 3, 6, 12 or 24 months,
depending on severity of retinopathy as determined by the
reviewing physician. Standard screening intervalswere 2 years
if no retinopathy was seen and decreasing with increasing
severity of retinopathy. Ambiguous photographic findings
and qualitatively unacceptable photographs led to patients
being recalled for a slit-lamp biomicroscopy examination.
From 2005 the screening procedure included transfoveal op-
tical coherence tomography in eyes with macular lesions
suggesting the presence of diabetic macular oedema.
Procedure for diagnosis of clinically significant macular
oedema Routine procedure was for a physician to review
the fundus photographs and to refer patients in need of or
suspected of being in need of photocoagulation or other
ophthalmic therapy to the Department of Ophthalmology at
Glostrup Hospital (Herlev Hospital prior to 2006) where the
decision to perform photocoagulation for diabetic macular
oedema was based on slit-lamp biomicroscopic findings.
Fluorescein angiography was used only to assist the planning
of photocoagulation therapy. Photocoagulation treatment
criteria were based on the outcome of the Early Treatment
Diabetic Retinopathy Study (ETDRS) and its definition of the
treatment threshold ‘clinically significant macular oedema’
(CSME) [19, 20]. Deviations from these guidelines could be
made at the treating physician’s discretion when ocular, sys-
temic or psychosocial conditions suggested it was relevant.
The study endpoint The endpoint was taken as the event of a
patient progressing to the patient’s first photocoagulation
treatment for CSME. Photocoagulation, rather than photo-
graphic detection of oedema, was used as the endpoint be-
cause stereoscopic biomicroscopy was considered the gold
standard diagnostic modality. The nominal date the endpoint
was reached when the patient was referred from the Steno
Diabetes Center (referral visit). Not all patients referred would
be treated with photocoagulation and, therefore, the registra-
tion of an event was made when the patient returned to the
screening programme at Steno. This procedure, together with
our interest in the change in risk factor levels from one visit to
the next, implies that patients with three visits or less were not
eligible for the analysis.
During the period of observation, primary treatment for
CSME other than photocoagulation was administered only
within controlled clinical trials and in patients with isolated
perifoveal sources of leakage who, in the opinion of the
physician, could not be safely treated by photocoagulation.
Incident macular oedema of a lesser severity than CSME was
not examined in this study.
Inclusion criteria Inclusion criteria were: (1) having partici-
pated in the retinopathy screening programme between 1988
and 2008; (2) having been followed by retinopathy screening
for at least 6 months; (3) using insulin; and (4) having been
diagnosed with diabetes before the age of 30 years.
Exclusion criteria Prior photocoagulation for diabetic macu-
lar oedema was an exclusion criteria. In addition, patients with
three or fewer visits at the screening clinic were excluded to
ensure a meaningful period of observation, which reduced the
study population from 2,324 to 1,878 patients. For patients
included in the study, visits were excluded from analysis if the
interval from the most recent previous visit was longer than
2.7 years, the 95% percentile for all screening intervals of the
initial dataset, because the information about metabolic con-
trol and blood pressure at the most recent previous visit was
deemed to be outdated. All following visits for that particular
patient were also excluded from analysis. This criterion ex-
cluded 73 events in patients who had reached the endpoint of
macular photocoagulation after an overdue screening visit,
thus leaving 297 patients with an event out of 1,878 patients
who were eligible for analysis.
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Systemic health Systemic health variables were retrieved from
the electronic patient record system of the Steno Diabetes
Center eye clinic. Visits within 1 week were regarded as one
visit taking place on the earliest of the visit dates (this occurred
for 30 patients). For most retinopathy screening visits, data
from a systemic examination and blood tests were available
from the same day. If not, such data were retrieved from the
most recent endocrinology visit, provided that it was no more
than 6months previous to the retinopathy visit. Endocrinology
visits were more frequent than retinopathy visits.
The analysis is based on the interval between visits as the
analytical unit. Macular oedema develops over time, and must
be regarded as present during an unknown fraction of the time
between the visit where the patient is referred for photocoag-
ulation and the previous visit. Inter-visit changes were defined
as the differences between the observed values of the risk
factors at the beginning of an interval (the current values)
and the values at the beginning of the previous interval.
Changes were evaluated as inter-visit change between suc-
cessive visits normalised to 6-monthly rates and analysed as
class variables for the primary analysis. The classes were based
on the quartiles for the event group, and owing to the approx-
imate symmetry and distribution, rounded to the nearest 0.5
percentage point for changes in HbA1c (corresponding to a
change of 5.5 mmol/mol), 10 mmHg for changes in systolic
blood pressure and 5 mmHg for diastolic blood pressure. A
total of 297 events was available for the analysis.
The reference range in healthy participants of the HbA1c
assay used at the Steno Diabetes Center was 4.1–6.4%, cor-
responding to 21.3–46.4 mmol/l.
Statistical analysis HbA1c, systolic blood pressure, diastolic
blood pressure and the inter-visit changes to these variables
were analysed as explanatory variables. Duration of diabetes
was grouped into 10 year intervals (for Table 1), except
duration <20 years, which constituted a single group because
it contained few events. Onset of diabetes before or after
puberty was calculated using age of onset of 12 years as cut-
off [21, 22]. Quantitative clinical data were analysed by non-
parametric Wilcoxon tests and the χ2 test was used for qual-
itative data. For the level of retinopathy, eyes progressing to
the event of photocoagulation were compared with the mean
of right and left eyes in non-progressing patients.
The analysis of the effect of metabolic control was made
using a discrete time proportional hazards model [23] assum-
ing a constant hazard of an event in each interval. A binomial
model was used with complementary log-log link and the
interval length as offset variable [23]. This model was appro-
priate because of the interval censored data, variation in inter-
visit intervals, and time-dependent explanatory variables. In
patients with events, all subsequent visits were deleted. Visits
without events served as controls. Results are given as HRs for
reaching the endpoint calculated from exponentiation of
estimates. The model evaluated the outcome of photocoagu-
lation for CSME and included as explanatory variables, in
addition to what has been described above, the calendar period
categorised into 5-year groups. The purpose was to adjust for
changes in procedures and practice during the period of ob-
servation, in particular for the earliest part, where the distinc-
tion between progression to photocoagulation for macular
oedema and progression to photocoagulation for prolifera-
tions was less accurate.
Covariates in the discrete time proportional hazards model
were entered as continuous variables and it was tested whether
the effects could be included as linear or squared, otherwise
they were entered as categorical variables as described above.
The HbA1c and blood pressure variables were analysed one by
one in univariate models adjusted for age, diabetes duration
and calendar period (1988–1992, 1993–1997, 1998–2002 and
2003–2008). Subsequently, they were also tested in a multiple
regression model.
There are missing values for the covariates. The main
analysis was based on the available data and, in addition, a
sensitivity analysis was carried out using multiple imputation.
Missing values were imputed using chained questions when
HbA1c or blood pressure values were missing for an eye
examination without an accompanying endocrinology exam-
ination. The procedure uses a sequence of univariate imputa-
tion methods with fully conditional specification of prediction
equations; in all six complete datasets the missing blood
pressure and HbA1c values were imputed and the change in
risk factors were calculated as for the original data.
In a separate analysis, the inter-visit changes were analysed
as continuous variables. This model was based on a piecewise
linear model, that is, linear splines with 3 knots; the knots are
placed in (1−0.5)/n , …,(n −0.5)/n percentiles taken over the
event data, where n (=3) is the number of knots.
Confidence intervals and p values for the quartiles are
given as Wald estimates. Reported p values are two-sided
and the level of statistical significance was set a priori to
0.05. All analyses were performed using SAS software (version
Table 1 Development of clinically significant diabetic macular oedema
in type 1 diabetic patients
Photocoagulation status Duration of diabetes (years) Total
0–19 20–29 30–39 40–49 ≥50
Never photocoagulated, n 524 453 328 205 71 1,581
Photocoagulated for CSME
n 27 101 100 52 17 297
Percentage of total 4.9 18.2 23.4 20.2 19.3 15.8
The table shows patients who reached their first referral for photocoagu-
lation for CSME by duration of diabetes at the time of the event and the
number of patients without CSME with the same duration of diabetes at
his or her most recent visit
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9.2, SAS Institute, Cary NC, USA). This retrospective study
did not require institutional review board approval under Dan-
ish law.
Results
Of the total population of 2,324 patients with type 1 diabetes,
1,878 were eligible for analysis. The median period of obser-
vation was 7.76 years, corresponding to a total follow-up of
15,431 patient-years, during which the patients had attended a
mean of one screening visit per year. The median age was
33.4 years and themedian duration of diabeteswas 18.34 years
at the patient’s first retinopathy screening visit.
Progression to first photocoagulation treatment for CSME
in a patient’s first eye occurred in 297 patients. The total
period of observation in patients who progressed to CSME
was 7.36 years (median), compared with a median of
7.78 years in patients who did not progress to CSME
(p =0.057). We do, however, see a difference in the length of
the last, event-free interval. In patients who were subsequently
referred for photocoagulation for CSME the median length of
the last interval was 0.63 years; in patients who did
not develop CSME, the matching interval was 1.31 years
(p <0.0001).
Photocoagulation for CSME was carried out in 156
(15.9%) of 980 men and in 141 (15.7%) of 898 women
(p =0.9). Photocoagulation for CSME was most likely to be
made after 30–40 years’ duration of diabetes (Table 1).
First visit to the screening clinic At the first visit, patients who
progressed to photocoagulation for CSME were younger at
the onset of diabetes than patients who did not (p =0.0005) but
older at their first visit and therefore of longer diabetes
duration when first seen at a retinopathy screening visit
(p <0.0001; Table 2). No retinopathy, or mild background
retinopathy with microaneurisms, were found at baseline in
76% of patients who did not receive photocoagulation for
CSME vs 43% of patients who did; thus eyes that eventually
progressed to photocoagulation for CSME had higher levels
of retinopathy than eyes that did not (p <0.0001).
Photocoagulated proliferative retinopathy at baseline was
present in less than 2% of the non-progressing patients vs
9% of patients progressing to CSME.
As listed in Table 2, progression to photocoagulation was
associated with higher HbA1c, higher systolic blood pressure
and higher diastolic blood pressure at the first screening visit
(p <0.01) in separate non-parametric tests.
Relation to period of observation variables During the period
of observation, median HbA1c increased non-significantly
from 8.7% to 8.8% (71.6 to 72.7 mmol/l) in patients who
progressed to photocoagulation for CSME (p >0.5, Table 2)
and decreased significantly from 8.4% to 8.2% (68.3 to
66.1 mmol/l) in the remainder of the study population
(p <0.0001). Systolic blood pressure was stable for patients
progressing to photocoagulation (p =0.4), whereas a small
increase was found in non-progressing patients. Diastolic
blood pressure decreased significantly in both groups during
the period of observation (p <0.005 and p <0.01 for
progressing and non-progressing patients, respectively).
Table 2 Clinical characteristics
at the patients first and last visit to
the screening centre
Except where otherwise shown,
data is given as median
(interquartile range [IQR]) for the
first visit at the screening centre
and the last visit, defined as the
last event-free visit for patients
with event and the corresponding
visit for patients without event
Statistical significance was
assessed by Wilcoxon’s test
Variable Never photocoagulated Progressed to photocoagulation p value
First screening visit
Patients included, n (%) 1,581 (84.19) 297 (15.81)
Male, n (%) 824 (52.12) 156 (52.53)
Age in years at onset of diabetes 15.37 (9.6, 22.78) 13.03 (8.28, 20.55) 0.0005
Age in years at first screening visit 32.15 (24.96, 42.38) 39.77 (31.26, 45.61) <0.0001
Duration of diabetes in years 16.82 (9.40, 26.5) 23.18 (17.68, 31.34) <0.0001
HbA1c, % 8.4 (7.5, 9.4) 8.7 (8.0, 9.8) 0.0010
HbA1c, mmol/mol 68.3 (58.5, 79.2) 71.6 (64.0, 83.6)
Systolic blood pressure, mmHg 130 (118, 142) 137 (125, 150) <0.0001
Diastolic blood pressure, mmHg 80 (70, 85) 84 (78, 90) <0.0001
Last screening visit
Duration of diabetes in years 25.89 (17.00, 35.71) 31.62 (24.68, 39.36) <0.0001
HbA1c, % 8.2 (7.5, 9.1) 8.8 (8.1, 9.5) <0.0001
HbA1c, mmol/mol 66.1 (58.5, 76.0) 72.7 (65.0, 80.3)
Systolic blood pressure, mmHg 131 (120, 145.5) 136 (127, 152) <0.0001
Diastolic blood pressure, mmHg 78 (70, 85) 80 (72, 88) 0.0010
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Discrete time proportional hazards model Using a discrete
time proportional hazards model, current values for HbA1c,
systolic blood pressure and diastolic blood pressure remained
significant risk factors for progression to photocoagulation for
CSME (HbA1c p <0.0001, systolic blood pressure p =0.0003,
diastolic blood pressure p =0.0038, duration p <0.0001;
Table 3, left column) when analysed separately and adjusted
for current age, calendar period and duration (univariate mod-
el). With the same model, changes for both HbA1c, and
systolic and diastolic blood pressure were all significant
(p <0.0001). In a multiple regression model containing all
three covariates (joint model), only current HbA1c remained
significant overall (p <0.0001; Table 3, right column). For the
effect of changes, both the change in HbA1c and systolic blood
pressure were significant (HbA1c change p =0.0002; systolic
blood pressure p <0.0001). Duration has both a linear and
squared effect as the effect levels out after approximately
40 years duration (Fig. 1).
There was no effect of diabetes onset before or after pu-
berty (p >0.2) (results not shown). As shown in Table 3, upper
and lower quartile changes in HbA1c were associated with
higher HRs for progression to CSME than the middle quar-
tiles, irrespective of the change being a decrease or an increase
(Table 3). The same U-pattern was found for changes in
systolic and diastolic blood pressure. These effects of changes
in HbA1c and systolic blood pressure remained significant in a
joint, multiple regression model including current HbA1c and
blood pressure.
If analysed as continuous variables (Fig. 1) the HRs for
HbA1c and systolic and diastolic blood pressure follow the
same pattern with minimal risk at zero change and fairly rapid
increase with changes in both directions, followed by smaller
effects on the risk for increasing changes. It should be noted
that the graph is computed by a piecewise linear model, giving
rise to distinct discontinuation points that do not reflect a
similar clinical effect of the covariate.
In a separate analysis, the risk factors were re-evaluated
including imputed values for the covariates.With this approach,
all 1,878 patients with 297 events were included in the analysis.
The HRs are summarised in Table 4 and show the same overall
conclusion as the analysis based only on the observed data.
Discussion
In agreement with several previous reports, this study of a
large diabetic retinopathy screening population found that
the risk of diabetic retinopathy progression to a level
that prompted photocoagulation for clinically significant
macular oedema increased with increasing diabetes duration,
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Fig. 1 (a–d) The effects of metabolic changes were entered into the
models as continuous variables, as described in the Methods. The curves
are calculated with a linear spline, i.e. a piecewise linear model, the HRs
(loge scale, solid line) and the 95% CIs (broken line) are shown from a
joint model similar to Table 3. (a–c) For both HbA1c and blood pressure,
the minimal risk for photocoagulation was found for zero changes, with
increasing risks both for decreases and increases in the variables. The
curves also suggest a peak in the hazard ratio for HbA1c changes of 0.5
percentage points (corresponding to a change of 5.5 mmol/mol) (a) and
10 mmHg for systolic (b) and 5 mmHg (c) for diastolic blood pressure,
with a plateau for larger changes. Due to the piecewise linear model, the
exact position of the peaks and the distinct discontinuation points should
be interpreted with caution. The HR for diabetes duration (d) reaches a
plateau after approximately 40 years
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glycaemia and blood pressure. The primary new information
provided by this study is that large changes in glycaemia,
systolic blood pressure and diastolic blood pressure occurring
one retinopathy screening interval before progression to
CSME, irrespective of whether they were decreases or in-
creases, were independent risk factors for CSME.
The effect of HbA1c change was studied in the 25 year
follow-up of the Wisconsin Epidemiological Study of Diabet-
ic Retinopathy. Based on 128 incident cases of clinically
significant diabetic macular oedema it was found that CSME
was associated with baseline HbA1c and with the increase in
HbA1c from baseline to year 4. No effect of a decrease in
HbA1c was reported [12].
The DCCT found that, during the first year on intensified
insulin therapy, progression of diabetic retinopathy was faster
than with conventional insulin therapy [13–15]. Thus, al-
though it was beneficial in the long run, a decrease in HbA1c
was associated with negative effects on an intermediate time
scale. The DCCT study population had little retinopathy at
baseline and few patients developed macular oedema during
the study and at later follow-up (Epidemiology of Diabetes
Interventions and Complications, EDIC), approximately 10%
of the 1,208 patients had received focal photocoagulation [24].
HbA1c variability measured in the DCCT study, but not glu-
cose variability, was a significant risk factor for microvascular
complications at the end of the EDIC study, but the timing of
macular oedema was not analysed in relation to the magnitude
and direction of changes in metabolic control [13–15].
The present study is the first large study to show that the
sight-threatening event of incident CSME is associated with
large changes in metabolic control. The finding that large
changes in metabolic control or blood pressure increased the
risk of CSME irrespective of direction was unanticipated.
In a clinical context it may be worth noting that the two
middle quartiles that fared better with respect to progression to
CSME were stable roughly within ±0.5 percentage point
change in HbA1c per 6 months, ±10 mmHg systolic blood
pressure per 6 months and ±5 mmHg diastolic blood pressure
Table 3 Effect of risk factors on the risk of progression to photocoagulation for CSME in patients with type 1 diabetes
Variable Events Univariate Joint model
HR 95% CI p value HR 95% CI p value
Duration (years) 297
Duration 1.18 1.11, 1.26 <0.0001 1.18 1.07, 1.30 0.0011
Duration squared 0.998 0.997, 0.99 0.0001 0.998 0.997,1.00 0.0262
Current HbA1c % 257 1.34 1.22, 1.47 <0.0001 1.49 1.30, 1.70 <0.0001
Current SBP (per 10 mmHg) 233 1.13 1.06, 1.21 0.0003 1.03 0.92, 1.16 0.5511
Current DBP (per 10 mmHg) 233 1.22 1.07, 1.39 0.0038 1.04 0.84, 1.29 0.7094
Change in HbA1c % per 6 months 211
≤−0.5 4.25 2.83, 6.38 <0.0001 3.04 1.85, 4.97 0.0002
>−0.5≤0 1.46 1.01, 2.11 1.37 0.88, 2.13
>0≤0.5 1 – 1 –
>0.5 2.84 1.85, 4.43 1.28 0.76, 2.16
Change in SBP per 6 months (mmHg) 170
≤−10 3.09 1.96, 4.86 <0.0001 2.59 1.50, 4.48 <0.0001
>−10≤0 1.20 0.79, 1.84 1.01 0.62, 1.63
>0≤10 1 – 1 –
>10 3.48 2.24, 5.41 2.49 1.48, 4.18
Change in DBP per 6 months (mmHg) 170
≤−5 2.39 1.49, 3.83 <0.0001 1.52 0.84, 2.76 0.3166
>−5≤0 1.39 0.91, 2.14 1.47 0.90, 2.39
>0≤5 1 – 1 –
>5 2.52 1.57, 4.02 1.51 0.88, 2.61
Models are adjusted for current year, age and duration of diabetes
Current HbA1c, systolic blood pressure (SBP) and diastolic blood pressure (DBP) are entered as continuous variables
For inter-visit changes in HbA1c and blood pressure, the changes are expressed the change per 6 months, corresponding to the mean event-free interval
preceding events. The changes are categorised and the HRs for progression to photocoagulation relative to the lowest scoring quartile are shown for each
quartile of each descriptive variable
For HbA1c, the change per 6 month interval of 0.5 percentage points (pp) is equal to a change of 5.5 mmol/mol
Because of missing data in the covariates the number of events in the joint model is less than in the univariate models (events in joint model=148)
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per 6 months. Compared with these patients, the outer quar-
tiles had a two- to threefold increased risk of CSME andwith a
quantitative analysis, the data indicates that relatively small
changes rapidly increases the risk, followed by a plateau for
large changes. The present study is a retrospective analysis,
based on registrations in the screening centre database.
Among other retrospective studies that may help guide endo-
crinology practice, Funatsu et al reported that, to minimise the
risk of progression of retinopathy, the rate of change in HbA1c
should not exceed 2 percentage points over 6 months [25]
while Ostri et al found that, to avoid diabetic papillopathy,
rates of change in HbA1c should not exceed –1.5 percentage
points per quarter year [26]. It is difficult to compact these
widely differing benchmarks into a single guideline figure for
all types of retinopathy progression; however the estimates in
the present study are fairly close to those of both Ostri et al and
Funatsu et al. Given the imperative need to improve metabolic
control in many patients with diabetes and the improved
resources for management of diabetic macular oedema we
support the conclusion of Funatsu et al and, as a clinical
guideline, we venture to propose that the 6 month changes
should be kept below the 2 percentage points for HbA1c to
minimise both progression of retinopathy and progression to
clinically significant macular oedema.
Arterial hypertension is a documented risk factor for reti-
nopathy [10, 11, 13], which may be taken to suggest that a
recent reduction in blood pressure should protect against
CSME, but our finding of the opposite effect is not unprece-
dented. A randomised controlled clinical trial found that
4 months losartan therapy in diabetic macular oedema was
associated with increased macular thickness compared to pla-
cebo [27]. We suspect that promotion of diabetic macular
oedema by antihypertensive medications may result from the
induction of retinal vasodilation and a consequent increase in
capillary pressure.
The limitations of the present retrospective study include
not having analysed the underlying causes of changes in
glycaemia and blood pressure, be they intensified insulin ther-
apy, concurrent systemic illness, progression of nephropathy
with secondary arterial hypertension, intervention against ne-
phropathy leading to a decrease in blood pressure, etc. Fur-
thermore, we did not examine the effects of changes in
Table 4 Sensitivity analysis of 297 events of progression to photocoagulation for CSME in patients with type 1 diabetes: the effect of risk factors based
on imputed datasets for HbA1c and blood pressure
Variable Events n=297 Univariate Joint model
HR 95% CI p value HR 95% CI p value
Duration (years)
Duration 1.18 1.11, 1.26 <0.0001 1.15 1.07, 1.22 <0.0001
Duration squared 0.998 0.997, 0.99 0.0001 0.998 0.998, 0.99 0.0012
Current HbA1c % 1.28 1.17, 1.40 <0.0001 1.28 1.17, 1.41 <0.0001
Current SBP (per 10 mmHg) 1.14 1.06, 1.21 0.0003 1.08 0.99, 1.18 0.0739
Current DBP (per 10 mmHg) 1.19 1.06, 1.34 0.0041 1.06 0.90, 1.25 0.4595
Change in HbA1c % per 6 months
≤−0.5 3.02 2.13, 4.29 <0.0001 2.39 1.64, 3.48 0.0004
>−0.5≤0 1.43 1.01, 2.00 1.59 1.11, 2.26
>0≤0.5 1 – 1 –
>0.5 2.61 1.80, 3.80 1.49 0.98, 2.25
Change in SBP per 6 months (mmHg)
≤−10 2.78 1.73, 4.48 <0.0001 2.14 1.30, 3.53 0.0019
>−10≤0 1.08 0.68, 1.70 1.12 0.70, 1.77
0≤10 1 – 1 –
>0 3.12 1.99, 4.91 1.94 1.19, 3.17
Change in DBP per 6 months (mmHg)
≤−5 2.40 1.54, 3.73 <0.0001 1.60 0.99, 2.59 0.1143
>−5≤0 1.25 0.83, 1.88 1.30 0.86, 1.98
>0≤5 1 – 1 –
>5 2.76 1.94, 3.94 1.61 1.09, 2.37
The analysis includes imputed values for missing information on HbA1c, systolic blood pressure (SBP) and diastolic blood pressure (DBP)
For HbA1c, the change per 6 month interval of 0.5 percentage points (pp) is equal to a change of 5.5 mmol/mol
The imputation is based on six imputed datasets and with this procedure, all 297 events are included in the analysis
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cholesterol, triacylglycerol and other lipids on the risk of
incident CSME [28].
In addition to confirming that duration of diabetes, high
levels of glycaemia and high blood pressure are risk factors for
progression of diabetic retinopathy, the present study found
that large changes in glycaemia and systolic blood pressure
were independent risk factors for progression to diabetic mac-
ular oedema in need of photocoagulation treatment. These
observations indicate that the role of metabolic and
haemodynamic stability in the development and progression of
diabetic retinopathy should be examined in prospective studies.
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